Back to Screener

Healthcare

PaxMedica, Inc. Common Stock(PXMD)

Live Price

Offline

$0.0005

-28.57% today

1Y Change

+600.00%

Window

Jun 23, 2025 โ†’ Jun 17, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
+61.7%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 23, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

PaxMedica, Inc. Common Stock (PXMD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 600.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.7%, free cash flow -77.4% with operating margin 0.0% and ROIC -415.6%. Stock Foundry combines PXMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PXMD

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PXMD Max Drawdown

-98.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PXMD and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

-0.21

Range -0.21 โ†’ -0.21

No analyst count

vs prior: +4.5%

Revenue Outlook

$0.0B

Range $0.0B โ†’ $0.0B

No analyst count

Consensus Spread

EPS spread0.0%
Revenue spreadโ€”

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

-0.21
Latest visible period
Q2 2026Q3 2027
6 visible pointstrend: +4.5%

Trend

Revenue trend

Average analyst revenue estimate

$0.0B
Latest visible period
Q2 2026Q3 2027
6 visible points

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.21
-0.21 to -0.21
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates
Q2 2027
Ends Jun 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.22
-0.22 to -0.22
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates
Q1 2027
Ends Mar 30, 2027
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.30
-0.30 to -0.30
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates
Q4 2026
Ends Dec 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.43
-0.43 to -0.43
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates
Q3 2026
Ends Sep 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.88
-0.88 to -0.88
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates
Q2 2026
Ends Jun 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.88
-0.88 to -0.88
No analyst count
EPS: No analyst count
Apr 30, 05:30 PM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.